Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM

Nivolumab: targeting PD-1 to bolster antitumor immunity

(2015) Julie R Brahmer et al.   Future Oncology

Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination

(2014) Yared Hailemichael et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Vaccine strategies for glioblastoma: progress and future directions

(2013) Christopher Jackson et al.   Immunotherapy

Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas

(2013) Jing Zeng et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Profound Impairment of Adaptive Immune Responses by Alkylating Chemotherapy

(2013) A. J. Litterman et al.   JOURNAL OF IMMUNOLOGY

Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-antigen-targeting anticancer vaccination

(2013) Adam J Litterman et al.   OncoImmunology

Regulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective

(2012) D. T. Le et al.   CANCER RESEARCH

Vaccine Injection Site Matters: Qualitative and Quantitative Defects in CD8 T Cells Primed as a Function of Proximity to the Tumor in a Murine Glioma Model

(2012) J. R. Ohlfest et al.   JOURNAL OF IMMUNOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide

(2011) Stuart A. Grossman et al.   CLINICAL CANCER RESEARCH

BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors

(2010) Thomas Reithmeier et al.   BMC CANCER

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy

(2009) Mary Lou Affronti et al.   CANCER

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY